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Invasive fungal infections (IFI) cause significant morbidity and mortality in patients undergoing hematopoietic stemfcell transplantation (HSCT) 
who have prolonged neutropenia or a severe graftf
versusfhost disease (GvHD) treated with highfdose 
corticosteroids and longfterm immunosuppressive 
therapy.1,2 The use of steroids for GvHD treatment 
represents a major risk factor for longfterm infections, 
with invasive aspergillosis (IA) as the principal cause 
of infectiousfrelated mortality.3,4 This suggests that eff
forts are warranted to develop optimal antifungal pref
ventive strategies after reducedfintensity conditioning 
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BACKGROUND AND OBJECTIVES: the liposomal formulation of amphotericin b (lamb) has been shown to 
cause few and mild infusion-related reactions, while achieving high plasma and tissue concentrations compared 
with conventional amphotericin b. We investigated the efficacy and safety of high-dose lamb (7.5 mg/kg once 
weekly) prophylaxis of fungal infections in allogeneic stem-cell transplanted (allo-sct) patients with graft-ver-
sus-host disease (Gvhd).
DESIGN AND SETTING: retrospective, comparative, single-center.
METHODS: forty-two patients receiving high-dose prednisone for Gvhd after allo-sct had lamb prophylaxis; 
83 patients in the control group received other antifungal prophylaxis.
RESULTS: in the lamb prophylaxis group, the median duration of treatment was 7 weeks. the cumulative inci-
dence of invasive fungal infection was 8% at 1 year after transplantation, 8% at 2 years and 16% at 3 years in 
the lamb group vs. 36% at 1 year, 44% at 2 years and 49% at 3 years in the other prophylaxis group (P=.008). 
fungal infection-related mortality after transplantation was observed in none of the patients in the lamb prophy-
laxis group vs. 12 patients (14%) at 1 year, 14 patients (17%) at 2 years and 16 patients (19%) at 3 years in the 
control group (P=.005). the tolerance of the treatment was good with only 5 patients (12%) having a reversible 
nephrotoxicity leading to temporary treatment discontinuation.
CONCLUSIONS: high-dose lamb prophylaxis seems effective and well tolerated in this short series of allo-sct 
patients with Gvhd. prospective clinical studies are required to confirm these results.
allogeneic stemfcell transplantation (allofSCT).5,6 We 
and others have previously shown that the use of high 
doses of corticosteroids for GvHD treatment represent 
a major risk factor for longfterm infections, with IA 
being the principal cause of infectiousfrelated mortalf
ity.3,4 The widespread use of prophylactic oral triazoles 
has limitations related to poor absorption, interfindif
vidual variability in metabolism and hepatic toxicity.7f9 
Oral triazoles are evaluated in this setting and voriconf
azole was evidenced recently to be more effective than 
fluconazole/itraconazole in preventing IFI in patients 
receiving corticosteroids for GvHD.10,11 
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For a long time, amphotericin B (AmB) deoxychof
late has been the best choice for antifungal prophylaxis 
due to its broad antifungal spectrum and minimal risk 
of resistance development. However, we used AmB def
oxycholate for many years, and it was associated with 
significant infusionfrelated toxicity and longfterm 
severe nephrotoxicity, which is a major limitation in 
allofSCT patients already receiving nephrotoxic drugs 
such as cyclosporin A.12,13
The liposomal formulation of amphotericin B 
(LAmB) has been shown to cause few and mild infuf
sionfrelated reactions,14f18 while achieving high plasma 
and tissue concentrations compared with conventional 
amphotericin B.15f17 The introduction of LAmB in the 
transplantation setting has increased the rate of theraf
peutic success of mycological infections with a good 
safety profile.19 
In two placebofcontrolled prophylactic trials, 
LAmB was effective for preventing fungal colonizaf
tion and invasive fungal infections, respectively, in 
allofSCT and liver transplantation.20 Moreover, recent 
studies have suggested that a once weekly highfdose of 
LAmB could be well tolerated as prophylactic antifunf
gal treatment in immunocompromized patients.21,22 In 
the present retrospective study, transplant patients 
with GvHD receiving a weekly high dose of LAmB 
for antifungal prophylaxis were compared to control 
patients receiving other antifungal prophylaxis with 
regards to efficacy and safety. 
PATIENTS AND METHODS
This was a retrospective study performed at the 
PaolifCalmettes Institute Cancer Centre, Unit of 
Transplantation and Cellular Therapy, Marseille, 
France. Patients who received highfdose prednisone 
(2 mg/kg/day) for acute and/or chronic GvHD 
therapy after allofSCT from 1 January 2003 to 31 
December 2007 were identified retrospectively. The 
weekly dose of 7.5 mg/kg was chosen because of the 
nonlinear pharmacokinetics of LAmB at higher dosf
es, and the fact that this dose is below the maximally 
tolerated dosage of LAmB.14 Most often, LAmB was 
administered on an outpatient basis. Patients were elif
gible for this prophylaxis schedule if they underwent 
allofSCT, and were receiving firstfline active cortif
costeroid therapy (2 mg/kg/day) for acute GvHD. 
LAmB infusions were started within 24f48h after the 
beginning of corticosteroid therapy. Patients had no 
previous history, evidence or suspicion of an invasive 
mycosis due to a filamentous fungus (ruled out by 
standard procedures),26 and had not received any othf
er concomitant antifungal prophylaxis. Also, patients 
were not treated with LAmB if (i) there was clinical 
and laboratory evidence of venofocclusive disease, (ii) 
serum creatinine was >1.5 times the upper limit of 
normal for age, (iii) hypokalemia was <3.0 mEq/L, 
and (iv) they had a history of anaphylaxis attributed 
to LAmB.22 This treatment was approved by the instif
Table 1. Characteristics of the patients and transplantations.
Characteristics
LAmB 
prophylaxis 
group
Other 
prophylaxis
group
Number of patients 42 83
Male/female 14/28 33/50
Age in years, median (range) 51 (18-70) 49 (18-66)
Diagnosis
   Acute myeloid leukemia 10 (24) 25 (30)
   Myelodysplastic syndrome 0 5
   Acute lymphoblastic leukemia 4 (10) 8 (10)
   Chronic myeloid leukaemia 2 2
   Myeloproliferative disease 3 1
   Non-Hodgkin lymphoma 9 (21) 12 (14)
   Hodgkin lymphoma 0 4
   Chronic lymphocytic leukemia 5 (12) 2 (2)
   Multiple myeloma 5 (12) 14 (17)
   Metastatic solid tumors 4 (10) 10 (12)
Graft source
   Bone marrow 2 (5) 10 (12)
   peripheral blood stem cells 34 (81) 64 (77)
   Umbilical cord blood 6 (14) 8 (10)
   Bone marrow + peripheral blood stem cells 0 1 (1)
Allogeneic stem cell transplantation
   Matched unrelated donor/umbilical cord blood 6/6 (29) 10/8 (22)
   Sibling 30 (71) 65 (78)
Conditioning regimen
   Standard 2 (5) 5 (6)
   reduced intensity conditioning 40 (95) 78 (94)
      Flu-Bu-ATG 22 36
      Flu-TBi 7 10
      Flu-Bu-TLi 1 16
      Others 10 16
Values are number (%) unless otherwise noted. Flu, fludarabine; Bu, busulfan; ATG, antithymocyte globulin; TBi, total 
body irradiation 2 Gy; TLi, total lymphoid irradiation. 
original research reportLAMB prOpHyLAxiS
Hematol Oncol Stem Cell Ther 3(4)     Fourth Quarter 2010 hemoncstem.edmgr.com 169
tutional review board and patients gave informed conf
sent for analysis of their clinical data. Standard 2008 
definitions for possible, probable and proven IFI were 
used.23
Supportive care was identical during the whole 
study period. Pneumocystis pneumonia prophylaxis 
consisted of trimethoprimfsulfamethoxazole (10 mg/
kg/day trimethoprim) administered at preftransf
plantation and when the neutrophil count exceeded 
500/µL twice weekly. As soon as the neutrophil count 
exceeded 500/µL, patients received daily oral amoxif
cillin prophylaxis (500 mg × 3/day) against encapsuf
lated bacteria. Antibacterial prophylaxis was disconf
tinued at the time of systemic immunosuppressive 
therapy discontinuation. Prophylaxis against herpes 
simplex virus included intravenous acyclovir (250 mg 
× 3/day) or oral valacyclovir (500 mg × 2/day) durf
ing the first month after allofSCT. Patients received 
fluconazole according to the attending physician decif
sion as part of our routine practice. Fluconazole (400 
mg/day) was given to patients without a history of IA, 
from the start of conditioning regimen until day 90 
after transplantation. 
Empiric broadfspectrum antibiotics were begun 
for temperature greater than 38.5°C or clinical signs 
of infection. Patients did not receive systematic or spef
cific oral digestive decontamination.5
A lyophilized preparation of LAmB (AmBisome, 
Gilead Sciences, Paris, France) was reconstituted acf
cording to the manufacturer’s instructions to give a 
2 mg/mL solution. Drug dilutions for injection were 
prepared as needed with 5% dextrose. All patients ref
ceived oncefweekly intravenous LAmB prophylaxis at 
a dose of 7.5 mg/kg as a 2 hourfinfusion. Toxicity was 
evaluated using the NCIfCTC score (National Cancer 
Institute Common Toxicity Criteria). 
The primary endfpoint of the study was the incif
dence of IFI; secondary endpoints included fungalf
related mortality, transplantfrelated mortality, overall 
survival and safety. All patients who received antifunf
gal prophylaxis were included in the efficacy and safety 
analyses. The KaplanfMeier method was used to esf
timate the endfpoints at different times of followfup 
and the Gray test (cumulative incidence of IFI, funf
galfrelated mortality, transplantfrelated mortality) or 
the logfrank test (overall survival) were used to comf
pare the differences between the LAmB prophylaxis 
group and the control group. The numbers of infecf
tions in the two treatment groups were compared by 
the Fisher exact test.
RESULTS 
Of 125 patients presenting with GvHD and treated 
with corticosteroids, the LAmB prophylaxis group 
included 42 patients (acute GvHD, 33 patients; 
chronic GvHD, 34 patients) who had received oncef
weekly highfdose LAmB (7.5 mg/kg) prophylaxis. 
The control group was composed of 83 patients (acute 
GvHD, 48 patients; chronic GvHD, 66 patients) who 
had received other systemic prophylaxis; some paf
tients had both acute and chronic GvHD. Except for 
acute GvHD, both groups were comparable (P=NS) 
as for age, disease characteristics, graft source, donor 
type, and the conditioning regimen intensity (Table 
1). Acute GvHD was more frequent in the LAmB 
Table 2. Transplantation outcome.
Characteristics
LAmB 
prophylaxis 
group
n (%)
Other 
prophylaxis
Group
n (%)
Acute GvHD  (P=.03617)  33 (79) 48 (58)
  Grade 2 (p=.5992) 19 (45) 32 (39)
  Grade 3-4 (p=.1294) 14 (33) 16 (19)
Chronic GvHD
  Limited 6 (14) 15 (18)
  Extensive 28 (67) 51 (61)
Fungal prophylaxis
  LAmB 42 (100) 0
  Fluconazole NA 59 (71)
  Voriconazole NA 6 (7)
  itraconazole NA 5 (6)
  Caspofungine NA 4 (5)
  posaconazole NA 2 (2)
  Not available NA 7 (8)
GvHD: graft-versus-host disease
Table 3.  invasive fungal infection outcomes at the last follow up 
after transplantation.
IFI
LAmB prophylaxis 
group
(n=42) (%)
Other prophylaxis
group
(n=83) (%)
possible 2 (5) 22 (27)
probable 4 (10) 11 (13)
proven 0 2 (2)
Total 6 (14) 35 (42)
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group (33/42; 79%) as compared to the control group 
(48/83; 58%) (P=.03617). Other relevant early transf
plantfrelated events are summarized in Table 2. The 
median dose of LAmB prophylaxis was 500 mg/week 
(range 300f650 mg/week) for a median duration of 7 
weeks of treatment (range 2f15 weeks).
The global incidence of IFI was 14% (6 patients) 
in the LAmB group vs. 42% (35 patients) in the conf
trol group (P=.002). According to diagnostic criteria 
and revised definitions of invasive fungal disease of 
EORTC/MSG consensus group, 23 in LAmB group, 
2 patients had possible IFI and 4 patients had probf
able IFI vs, in control group, 22 patients with possible 
IFI and 11 patients with probable IFI. Only 2 patients 
had proven IFI, both in the control group (Table 3). 
The outcomes in the two groups at the last follow 
up are summarized in Table 4.The cumulative incif
dence of IFI was 8% at 1 year after transplantation, 
8% at 2 years and 16% at 3 years in the LAmB group 
vs. 36% at 1 year, 44% at 2 years and 49% at 3 years 
in the control group (P=.008) (Figure 1). The cause 
of death by infection, alone or with GvHD, in two 
groups at the last follow up is summarized in Table 
5. No fungal infectionfrelated mortality after transf
plantation was observed in LAmB group vs. 12 deaths 
(14%) related to fungal infection at 1 year, 14 deaths 
(17%) at 2 years and 16 deaths (19%) at 3 years in the 
control group (P=.005) (Figure 1). There was no diff
ference between the transplantfrelated mortality rates 
in the two groups: 18% from 1 year through 3 years 
after transplantation in the LAmB group vs. 16% at 1 
year, 19% at 2 years and 21% at 3 years in the control 
group (P=.99)(Figure 2).There was no difference bef
tween the overall survival rates in the two groups: 69% 
at one year after transplantation, 55% at 2 years and 
55% at 3 years in the LAmB group vs. 75% at one year, 
64% at 2 years and 58% at 3 years in the control group 
(P=.60)(Figure 2).
The tolerance of the treatment was good. Toxicity 
was observed in only 5 patients (12%) who had nephf
rotoxicity, which led to temporary treatment disconf
tinuation but was reversible. All patients were taking 
concomitantly cyclosporin A or other nephrotoxic 
drugs such as ganciclovir, amikacin or vancomycin. 
DISCUSSION 
This study evaluated the efficacy and safety of oncef
weekly prophylactic administration of highfdose (7.5 
mg/kg) LAmB in adult patients treated in our instituf
tion, receiving highfdose corticosteroids for acute or 
chronic GvHD therapy after allofSCT.
One report suggested that antifungal prophylaxis 
Table 4. Outcome at the last follow up after transplantation.
 Outcome 
L-AmB 
prophylaxis 
group
(n = 42)
Other 
prophylaxis 
group
(n = 83)
P
 Overall Survival   
   At 1 year  67% 58%
 .256 
   At 2 years 55% 42%
 Causes of death, n (%)    
   Underlying hematological 
   disease 9 (21%) 16 (19%)  NS
   infection 1 (2%) 10 (12%) .3370
   GvHD 2 (5%) 3 (4%) 1
   infection plus GvHD 2 (5%) 5 (6%)  NS
   Multi-organ failure 3 (7%) 1 (1%)  NS
 Transplant-related mortality   
   At 1 year 13% 15%
 .671
   At 2 years                            25% 29%
 Fungal-related mortality   
   At 1 year 0 14%
.005 
   At 2 years 0 17%
Table 5. Cause of death by infection at the last follow up after 
transplantation.
Cause of death by 
infection
L-AmB 
prophylaxis 
group
(n=42)
Other 
prophylaxis 
group
(n=83)
 Total 3 (7%) 15 (18%)
 Infection alone 1 (2%) 10 (12%)
   Viral  (CMV) 1 2
   Bacterial  
   (Staphylococcus aureus) 0 1
   iFi proven 0 1
   iFi probable 0 2
   iFi possible 0 4
 Infection plus GvHD 2 (5%) 5 (6%)
   Viral  (CMV) 2 1
   Bacterial (Enterobacter) 0 1
   iFi proven 0 0
   iFi probable 0 0
   iFi possible 0 3
Values are number (%) unless otherwise noted. NS=Not statistically significant.
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with lowfdose LAmB is feasible and effective in paf
tients undergoing intensive chemotherapy.24 Another 
study showed that a oncefweekly 15 mg/kg LAmB 
dose given to adult patients undergoing allofSCT 
achieved high, sustained tissue concentrations, simif
lar to those achieved with conventional (1 mg/kg) 
daily dosing (Gubbins et al., abstract at the 44th 
Interscience Conference on Antimicrobial Agents and 
Chemotherapy, 2004).
The schedule of a single dose 7.5 mg/kg once weekly 
was chosen because of the nonlinear pharmacokinetics 
of LAmB at higher doses, as well as because this dose 
is below the maximumly tolerated dose of LAmB.14 
However, one challenging aspect of our study was the 
need for weekly intravenous administration of LAmB 
as compared to oral administration with new triazoles 
such as voriconazole or posaconazole. Alternative prof
phylactic therapy with an echinocandin (ex, caspofunf
gin) requires daily intravenous administration. 
If ambulatory weekly highfdose LAmB proved to 
be tolerable, this would provide an acceptable prophyf
lactic regimen which could be administered for long 
periods, further improving the safety and outcome of 
RIC or myeloablative allofSCT. Moreover LAmB has 
a broad spectrum of action against molds and yeasts 
including Candida spp., Aspergillus spp. and filamenf
tous fungi such as zygomycetes and could thus offer 
larger antifungal prophylaxis.25 
The incidence of IFI and fungal infectionfrelated 
mortality were significantly reduced in the LAmB 
prophylaxis group compared to the control group. 
However, we did not observe any difference in overall 
survival and in transplantfrelated mortality between 
the two groups. This could be due to the higher fref
quency of acute GvHD in the LAmB prophylaxis 
group compared to the control group. 
In contrast with reports of concerns about a high 
rate of hypokalemia, our data indicate that LAmB can 
be given safely at high doses.14 Toxicity was observed 
in 5 patients (12%) who had a reversible nephrotoxicf
ity which led to temporary treatment discontinuation. 
All patients were taking concomitantly nephrotoxic 
drugs. 
This study has the limitations inherent to a retrof
spective analysis of a nonfrandomized study. Moreover 
the incidence of IFI in the control group could appear 
high (36% after one year). We cannot exclude that 
IFI was overdiagnosed, particularly for possible IFI. 
It should be kept in mind that these patients were at 
high risk of fungal infections: they were not only allof
SCT patients, but they had also severe GvHD and 
therefore received highfdose corticotherapy. The inf
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Figure 1. Cumulative incidence of invasive fungal infections and fungal infection-related 
mortality according to antifungal prophylaxis. 
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Figure 2. Overall survival and transplant-related mortality (TrM) according to antifungal 
prophylaxis.
fectionfrelated mortality, which is independent of the 
initial diagnosis, was clearly lower for the group with 
LAmB prophylaxis (0% vs. 14% for the control group 
after one year). 
We present the patient outcomes with a followf
up of 3 years after transplantation even though these 
data are most probably well beyond the pharmacof
logical effect expected for a median 7fweek treatment. 
Nevertheless we estimate that this longfterm followf
up is important evidence that the choice of prophylaxf
is is associated with durable and different outcomes. 
Despite the limitations of this study and the short sef
ries of patients, LAmB prophylaxis of IFI seems effecf
tive and well tolerated reducing both the incidence of 
IFI and the fungal infectionfrelated mortality in allof
SCT patients presenting as severe GvHD. Further 
prospective clinical studies are required to confirm 
these singlefcenter data.
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